The Relationship between Golgi Protein 73, Alpha-Fetoprotein, Liver Function Indicators, and Traditional Chinese Medicine Syndrome Types of Primary Liver Cancer

Abstract

Objective Our objective was to analyze the correlation between Golgi protein 73 (GP73), alpha-fetoprotein (AFP), liver function indicators, and traditional Chinese medicine (TCM) syndrome types of primary liver cancer (hereinafter referred to as “liver cancer”).

Methods In total, 156 liver cancer patients (liver cancer group) and 52 healthy individuals (health group) were selected as the research subjects to detect their GP73, AFP expression, and liver function-related indicators. The obtained data were statistically analyzed using SPSS 21.0 software.

Results (1) The positive expression rate of GP73 in the liver cancer group was 50%; the positive expression rates of qi stagnation and blood stasis syndrome, heat toxin in liver and gallbladder syndrome, and yin deficiency of liver and kidney syndrome were 37.9, 54.3, and 59.6%, respectively. There was no statistically significant difference between the groups (p > 0.05). The positive expression rate of AFP was 50%. The positive expression rates of qi stagnation and blood stasis syndrome, heat-toxin in liver and gallbladder syndrome, and yin deficiency of liver and kidney syndrome were 41.7, 54.3, and 59.6%, respectively. There was a statistically significant difference between the groups (p < 0.05). (2) The GP73 levels of patients with different syndrome types in the liver cancer group were ranked from high to low as yin deficiency of liver and kidney syndrome, heat toxin in liver and gallbladder syndrome, and qi stagnation and blood stasis syndrome. The differences between the groups were statistically significant (p < 0.05). The AFP levels of patients with different syndrome types in the liver cancer group were ranked from high to low as heat toxin in liver and gallbladder syndrome, yin deficiency of liver and kidney syndrome, and qi stagnation and blood stasis syndrome. There was no statistically significant difference between the groups (p > 0.05). (3) Analysis of liver function indicators in the liver cancer group: the alanine transaminase (ALT) levels of patients with different syndrome types were in descending order from high to low, including yin deficiency of liver and kidney syndrome, heat toxin in liver and gallbladder syndrome, and qi stagnation and blood stasis syndrome. The differences between groups were statistically significant (p < 0.05). The aspartate aminotransferase (AST) levels of patients with different syndrome types were ranked from high to low as follows: heat toxin in liver and gallbladder syndrome, yin deficiency of liver and kidney syndrome, and qi stagnation and blood stasis syndrome. The difference between groups was statistically significant (p < 0.05). The levels of albumin (ALB) in patients with different syndrome types were ranked from high to low, including heat toxin in liver and gallbladder syndrome, qi stagnation and blood stasis syndrome, and yin deficiency of liver and kidney syndrome. The differences between groups were statistically significant (p < 0.05).

Conclusion GP73 and indicators such as ALT, AST, and ALB are of great significance in the diagnosis of TCM syndrome differentiation and classification of liver cancer patients.

Keywords

primary liver cancer - Golgi protein 73 - alpha-fetoprotein - liver function - TCM syndrome types

Authors' Contribution

B.L. was responsible for conceptualization, methodology, project administration, and writing-original draft. J.R. was responsible for formal analysis, investigation, validation, and writing-original draft. H.L. was responsible for funding acquisition, supervision, Writing-review & editing.

Publication History

Received: 10 August 2023

Accepted: 27 September 2023

Article published online:
28 December 2023

• References

• 1 Fan XR, Liu MJ, Wang Q. et al. Pathogenesis and treatment progress of primary liver cancer. Chin Hepatol 2023; 28 (04) 391-392
• 2 Shao HY, Peng MJ, Chen G. et al. Age-period-cohort modeling study on the mortality of hepatic carcinoma from 1991 to 2011. China J Cancer Prev Treat 2016; 23 (22) 1465-1469
• 3 Zhang XY, Huang P, Li YJ. et al. Progress of therapies for the advanced hepatocellular carcinoma. J Mod Oncol 2017; 25 (10) 1655-1659
• 4 Ma J, Zhang AY, Wang Y. et al. Golgi protein 73 in AFP-negative diagnosis of primary liver cancer patients. Ningxia Med J 2017; 39 (04) 298-300
• 5 Kladney RD, Bulla GA, Guo L. et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 2000; 249 (1–2): 53-65
• 6 Chen X, Cai J. An interpretation of diagnostic and treatment guidelines for primary liver cancer (2017 Edition). Electron J Liver Tumor 2017; 4 (03) 1-5
• 7 Tian DL, Cai G. Internal Medicine of Traditional Chinese Medicine. Shanghai: Shanghai Science and Technology Press; 2013: 268-417
• 8 Wang CX, Gao J. Serum Golgi protein 73, lentil lectin-reactive alpha-fetoprotein-L3, AFP and α-L- fucosidase levels in patients with primary liver cancer. Shiyong Ganzangbing Zazhi 2019; 22 (01) 113-116
• 9 Cui Q, Dong YE, Huo YL. et al. Simultaneous detection of serum Alfa fetoprotein, Golgi glycoprotein 73, serum ferritin, and des-gamma-carboxyprothrombin in the diagnosis of primary liver cancer. Zhongguo Yike Daxue Xuebao 2019; 48 (05) 434-436
• 10 Song W. Clinical significance of combined detection of serum AFP, GP73, AFU and IL-8 in the diagnosis of primary hepatic carcinoma. Chin J Clin Electron Ed 2016; 10 (09) 1266-1270
• 11 Li XH, Wang QS, Liu AJ. et al. Changes of serum AFP, AFU, TSGF and GP73 levels in patients with primary liver cancer and their CT features. Hainan Med J 2019; 30 (19) 2473-2475
• 12 Jia Y. Correlation between depression and the risk of occurrence and recurrence of liver cancer. Changchun: Jilin University; 2019
• 13 Liu HT, Zhao WR, Zhang WQ. et al. The clinical investigation of depression situation of patients suffering from different systemic oncology. J Kunming Med Univ 2019; 40 (11) 142-146
• 14 Ou J, Chen C, Hu LR. et al. Research on relationship between AFP and TCM pattern of syndrome in 175 patients with primary liver cancer. China Ind Econ 2015; 21 (23) 29-31
• 15 Qiao LJ, Shao MY. Preliminary study on the relationship between TCM syndromes of primary liver cancer and serum AFP and VEGF. China J Chin Med 2019; 34 (03) 595-599
• 16 Li ZL, Shi HY, Wu CY. Research progress on the correlation between objective examination indexes and syndrome types of primary liver cancer. Jiangsu J Tradit Chin Med 2016; 48 (09) 83-85
• 17 Shao JY, Huang HJ, Jiang PY. et al. Research progress on correlation between TCM syndrome types and auxiliary examination indexes of primary hepatocellular carcinoma. Basic Tradit Chin Med 2023; [phone]
• 18 Fang ZQ, Li YJ, Tang CL. et al. Analysis on characteristics of syndrome in 2060 cases of primary hepatic cancer. J Tradit Chin Med 2004; 45 (01) 53-54
• 19 Liu JL, Li Y, Wang LK. et al. A study of distribution rules of Chinese Medicine syndrome in 105 patients with primary liver cancer. J New Chin Med 2019; 51 (06) 23-25
• 20 Xu MX. Correlation between TCM syndrome types and objective laboratory indexes in patients with primary liver cancer. Hefei: Anhui University of Chinese Medicine; 2019